Immix Biopharma (IMMX) Cash from Financing Activities (2021 - 2026)

Immix Biopharma has reported Cash from Financing Activities for 6 years, with the latest figure at -$37561.0 in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to -$37561.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.2 million (changed N/A YoY) and the FY2025 annual result came in at $107.4 million, up 573.33% from the prior year.
• Cash from Financing Activities slipped to -$37561.0 in Q1 2026 per IMMX's latest filing, from $95.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $95.7 million in Q4 2025 and troughed at -$105963.0 in Q2 2022.
• A 5-year average of $12.8 million and a median of $2.9 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 228.71% in 2022, then jumped 13311.62% in 2024.
• Over 5 years, Cash from Financing Activities stood at $424276.0 in 2022, then surged by 38.28% to $586692.0 in 2023, then soared by 2618.39% to $15.9 million in 2024, then soared by 499.86% to $95.7 million in 2025, then slumped by 100.04% to -$37561.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$37561.0, $95.7 million, and $10.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.